Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

NKTR

Phase 2b

Rezpegaldesleukin (NKTR-358)

Severe to Very Severe Alopecia Areata

H2 2025

REZOLVE-AA trial. 3/5/24- Ph2b initiated. 2/26/25- Completed target enrollment. 3/12/25- Topline data in H2 2025.

Data readout

PRME

Phase 1/2

PM359

p47[phox] Chronic Granulomatous Disease (CGD)

2025

4/29/24- IND cleared. 2/28/25- Initial data in 2025.

Data readout

TBPH

Phase 3

Ampreloxetine (TD-9855)

Multiple System Atrophy (MSA) with Neurogenic orthostatic hypotension (nOH)

2025

CYPRESS study. 8/5/24- Last patient into the open-label portion of CYPRESS in mid-2025, topline data ~6 months later. Prepare expedited NDA filing post readout and to request priority review.

Data readout

VRTX

Phase 1/2

Povetacicept

Autoimmune glomerulonephritis (IgAN, pMN, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis)

2025

RUBY-3 Basket Study. 10/25/24- Presented trial update at ASN 2024 on October 24, 2024. 2/10/25- Data in 2025.

Data readout

NMRA

Phase 1b

NMRA-511

Alzheimer’s Disease Agitation

H2 2025

6/20/24- Initiated Ph1b trial. 11/12/24- Data in H2 2025.

Data readout

ELDN

Phase 2

Tegoprubart (AT-1501)

Kidney transplantation

Q4 2025

BESTOW trial. 11/2/23- Enrolled 1st patient in Ph2 OLE . 6/3/24 Present updated data at ATC '24. 1/13/25- Completed patient enrollment w/ topline results in Q4 2025.

Data readout

AUTL

Phase 1

AUTO1/22 (CD19 & CD22)

Pediatric ALL (Acute lymphoblastic leukemia)

H2 2025

Longer follow up data presented at ASH '22. Additional data at EBMT 2023. Initial data in H2 2025.

Data readout

SNDX

Phase 1

Revumenib w/ 7+3 cytarabine + daunorubicin

AML (Acute Myeloid Leukemia)

H2 2025

Initiated trial in Q2 '24. 1/13/25- Report data in H2 2025.

Data readout

GPCR

Phase 2b

GSBR-1290 (GLP-1R agonists)

Type 2 diabetes & obesity

Q4 2025

ACCESS & ACCESS II trials. 6/3/24- Positive Full 12-wk obesity data. 11/13/24- Dosed first patient in ACCESS trial. To dose first patient in ACCESS II trial by YE 2024. Topline data for both trials in Q4 2025.

Data readout

QNCX

Phase 3

EryDex

Ataxia-Telangiectasia (A-T)

YE 2025

NEAT trial. 6/3/24- Received fast track designation. 6/25/24- First patient dosed. 11/13/24- Present Ph3 prior data at ICAR 2024. 2/7/25- Complete enrollment in Q2 2025 and topline data before YE 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20